Dr Antonio Passaro (European Institute of Oncology, Milan, Italy) and Prof Martin Reck (Lung Clinic Grosshansdorf, Grosshansdorf, Germany) discuss the IMpower133 study. This study is an exploratory analysis of maintenance therapy in patients with extensive-stage small-cell lung cancer, which was presented at WCLC 2020.
Prof Reck explains that in the Phase I/III IMpower133 study adding atezolizumab (anti–PD-L1) to carboplatin etoposide followed by atezolizumab maintenance for the first-line treatment of ES-SCLC led to significant overall survival (OS) and progression-free survival improvement vs placebo CP/ET.
In this analysis, he reports that they explored the benefit of atezolizumab vs placebo in the patients who reached the maintenance phase of IMpower133. They then talk about the updates from the IMpower133 study and what it means for patients with small cell lung cancer.
They further discuss the efficacy of atezolizumab and what treatment options are available for SCLC patients. Finally, the future of the IMpower133 study and other possible drug combinations are discussed.
This programme has been supported by an unrestricted educational grant from Roche.